ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bristol-Myers Squibb and the drug-development accelerator BioMotiv have launched Anteros Pharmaceuticals, a biotech firm developing drugs for fibrosis and inflammatory diseases. The start-up, which is based on technology developed at Yale University, is the first company to come out of a pact forged last fall between BMS and BioMotiv, which aims to advance discoveries made at research institutions. Bringing a molecule from the academic licensing stage to the clinic can cost $5 million to $7 million, a cost that the partners will share, BioMotiv CEO Satish Jindal says.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X